Pharma deal potentially great news, but there are worries over funding

Daniel Elkeles responds to the UK-US pharmaceuticals deal.

  • Finance

  • Prevention

Responding to the announcement of the UK-US pharmaceuticals deal, the chief executive of NHS Providers, Daniel Elkeles, said:

"This deal is potentially very good news for patients, for the NHS and for UK life sciences.

"It is great that NHS patients will have increased access to groundbreaking new treatments.

"The announcement also builds on the longstanding close partnership between the NHS and the pharmaceutical industry, making this the best place in the world to carry out clinical trials.

"However it is not yet clear how it will be paid for.

"There is absolutely no slack in current published NHS spending plans for this major commitment and that is a real worry for trust leaders."

Related articles

0/0
  • Training
    Abstract background with curved blue and green tones in NHS Providers’ brand style, featuring the Board Development programme logo.

    NHS finance for senior leaders

    3 March 20279:30 - 16:00Online

    Develop a greater understanding of NHS financial principles, funding flows and reporting to strengthen your confidence to effectively contribute at board level.

    • Leadership

    • Finance

  • Network

    NHS Chief Finance Officers and Commercial Leaders Forum

    2 December 202610:00 - 11:30Online

    An opportunity for NHS finance and commercial leaders to connect in a safe space, share strategic reflections, and explore national leadership priorities together.

    • Finance

  • Conference
    Young man receiving healthcare

    The NHS and Youth Participation Conference

    19 November 202610:00 - 16:00In-person

    Delivering the Milburn Review: How the NHS can create opportunity, improve health and strengthen local economies

    • Health inequalities

    • Improvement

    • Leadership

    • Mental health

    • Prevention

    • Workforce